121 related articles for article (PubMed ID: 21651645)
21. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
22. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Yoshimoto A; Kasahara K; Nishio M; Hourai T; Sone T; Kimura H; Fujimura M; Nakao S
Jpn J Clin Oncol; 2005 May; 35(5):233-8. PubMed ID: 15886272
[TBL] [Abstract][Full Text] [Related]
23. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
26. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
[TBL] [Abstract][Full Text] [Related]
27. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
28. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen as prognostic factor for metastatic non-small cell lung cancer by percutaneous cryosurgery.
Li H; Tang K; Niu L; Liang Y; Li J; Chen J; Xu K
Cancer Biomark; 2013; 13(5):337-43. PubMed ID: 24440973
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Zhang Y; Zhang L; Xu F; Wang ZQ; Zhao HY; Guan ZZ; Xu GC; Pan ZK
Ai Zheng; 2006 Dec; 25(12):1561-4. PubMed ID: 17166387
[TBL] [Abstract][Full Text] [Related]
31. [Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status].
Fischer JR; Geiger D; Haffner UJ; Lahm H
Pneumologie; 2007 Apr; 61(4):264-9. PubMed ID: 17455141
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Wen ZS; Chen XQ; Wu HY; Wei WD; Rong TH
Ai Zheng; 2007 Apr; 26(4):415-7. PubMed ID: 17430664
[TBL] [Abstract][Full Text] [Related]
34. An approach of selecting appropriate markers from the primary tumor to enable detection of circulating tumor cells in patients with non-small cell lung cancer.
Warawdekar UM; Sirajuddin MM; Pramesh CS; Mistry RC
J BUON; 2015; 20(3):782-90. PubMed ID: 26214631
[TBL] [Abstract][Full Text] [Related]
35. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
37. [Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Zhao YY; Zhang Y; Zhao HY; Wu JX; Jiang W; Xue C; Zhang L
Ai Zheng; 2009 Jun; 28(6):626-31. PubMed ID: 19635201
[TBL] [Abstract][Full Text] [Related]
38. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
[TBL] [Abstract][Full Text] [Related]
39. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
